Independent and combined effects of aerobic exercise and pharmacological strategies on serum triglyceride concentrations: A qualitative review

Physician and Sportsmedicine

Volumn 37, Issue 1, 2009, Pages 11-19

  Plaisance, Eric P ^a   Grandjean, Peter W ^a   Mahurin, A Jack ^b  

^a AUBURN UNIVERSITY   (United States)

^b Baptist Hospital   (United States)

Author keywords

Blood lipids; Niacin; Omega 3 fatty acids; Physical activity; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; G PROTEIN COUPLED RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

AEROBIC EXERCISE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; ENZYME ACTIVITY; EXERCISE; FLUSHING; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LIPOGENESIS; LIVER TOXICITY; METABOLIC SYNDROME X; NONHUMAN; PHYSICAL ACTIVITY; REVIEW; SIDE EFFECT; SKELETAL MUSCLE; TRIACYLGLYCEROL BLOOD LEVEL;

ANTILIPEMIC AGENTS; COMBINED MODALITY THERAPY; EXERCISE; FATTY ACIDS, OMEGA-3; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN LIPASE; NIACIN; POSTPRANDIAL PERIOD; TRIGLYCERIDES;

EID: 75849163636     PISSN: 00913847     EISSN: None     Source Type: Journal    
DOI: 10.3810/PSM.2009.04.1678     Document Type: Review

References (77)

1. LaRosa JC, He J, Viippitturi S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282(24): 2340-2346.
2. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62(5):707-714.
3. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007;176(8):1113-1120.
4. Assmann G, Cullen P, Schulte H. The Münster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J. 1998;(19 suppl A):A2-A11.
5. Criqui MH, Heiss G, Cohn R, et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med. 1993;328(17):1220- 1225.
6. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996:3 (2):213-219.
7. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation. 1979;60(3):473-485.
8. Patsch JR, Miesenböck G, Hopferwieser T, et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb. 1992;12(11):1336-1345.
9. Wideman L, Kaminsky LA, Whaley MH. Postprandial lipemia in obese men with abdominal fat patterning. J Sports Med Phys Fitness. 1996;36(3):204-210.
10. Gill JM, Hardman AE. Exercise and postprandial lipid metabolism: an update on potential mechanisms and interactions with high-carbohydrate diets (review). J Nutr Biochem. 2003;14(3):122-132.
11. Durstine JL, Grandjean PW, Cox CA, Thompson PD. Lipids, lipoproteins, and exercise. J Cardiopulm Rehabil. 2002;22(6):385-398.
12. Durstine JL, Grandjean PW, Davis PG, Ferguson MA, Alder son NL, DuBose KD. Blood lipid and lipoprotein adaptations to exercise: a quantitative analysis. Sports Med. 2001 ;31( 15):1033-1062.
13. Grandjean PW, Crouse SF, Rohack JJ. Influence of cholesterol status on blood lipid and lipoprotein enzyme responses to aerobic exercise. J Appl Physiol. 2000;89(2):472-480.
14. Després JP, Pouliot MC, Moorjani S, et al. Loss of abdominal fat and metabolic response to exercise training in obese women. Am J Physiol 1991;261(2ptl):E159-E167.
15. Haskell WL. The influence of exercise on the concentrations of triglyceride and cholesterol in human plasma. Exerc Sport Sci Rev. 1984;12:205-244.
16. Holloszy JO, Skinner JS, Toro G, Cureton TK. Effects of a six month program of endurance exercise on the serum lipids of middle-aged man. Am J Cardiol. 1964;14:753-760.
17. Crouse SF, O'Brien BC, Grandjean PW, Lowe RC, Rohack JJ, Green JS. Effects of training and a single session of exercise on lipids and apolipoproteins in hypercholesterolemic men. J Appl Physiol. 1997;83(6):2019-2028.
18. Thompson PD, Cullinane E, Henderson LO, Herbert PN. Acute effects of prolonged exercise on serum lipids. Metabolism. 1980;29(7):662-665.
19. Herd SL, Lawrence JE, Malkova D, Murphy MH, Mastana S, Hardman AE. Postprandial lipemia in young men and women of contrasting training status. J Appl Physiol. 2000;89(5):2049-2056.
20. Tsetsonis NV, Hardman, AE, Mastana SS. Acute effects of exercise on postprandial lipemia: a comparative study in trained and untrained middle-aged women. Am J Clin Nutr. 1997;65(2):525-533.
21. Hardman AE, Lawrence JM, Herd SL. Postprandial lipemia in endurance-trained people during a short interruption to training. J Appl Physiol. 1998;84(6):1895-1901.
22. Seip RL, Mair K, Cole TG, Semenkovich CF. Induction of human skeletal muscle lipoprotein lipase gene expression by short-term exercise is transient. Am J Physiol 1997;272(2 pt 1):E255-E261.
23. Kantor MA, Cullinane EM, Herbert PN, Thompson PD. Acute increase in lipoprotein lipase following prolonged exercise. Metabolism. 1984;33(5):454-457.
24. Zhang JQ, Smith B, Langdon MM, et al. Changes in LPLa and reverse cholesterol transport variables during 24-h postexercise period. Am J Physiol Endocrinol Metab. 2002;283(2):E267-E274.
25. Thompson PD, Yurgalevitch SM, Flynn MM. Effect of prolonged exercise training without weight loss on high-density lipoprotein metabolism in overweight men. Metabolism. 1997;46(2):217-223.
26. Zmuda JM, Yurgalevitch SM, Flynn MM, et al. Exercise training has little effect on HDL levels and metabolism in men with initially low HDL cholesterol. Atherosclerosis. 1998;137(1):215-221.
27. Fukuda N, Tojho M, Hidaka T, Sho H, Sugano M. Reciprocal responses to exercise in hepatic ketogenesis and lipid secretion in the rat. Ann Nutr Metab. 1991;35(4):233-241.
28. Gill JM, Mees GP, Frayn KN, Hardman AE. Moderate exercise, post-prandial lipaemia and triacylglycerol clearance. Eur J Clin Invest. 2001;31(3):201-207.
29. Mondon CE, Dolkas CB, Tobey T, Reaven GM. Causes of the triglyceride-lowering effect of exercise training in rats. J Appl Physiol. 1984;57(5):1466-1471.
30. Malkova D, Evans RD, Frayn KN, Humphreys SM, Jones PR, Hardman AE. Prior exercise and postprandial substrate extraction across the human leg. Am J Physiol Endocrinol Metab. 2000;279(5):E1020-E1028.
31. Knopp RH. Clinical profiles of plain versus sustained-release niacin (Niaspan) and the physiologic rationale for nighttime dosing. Am J Cardiol. 1998;82(12):24U-28U.
32. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med. 2004;164(7):697-705.
33. Goldberg A, Alagona P Jr, Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol. 2000;85(9):1100-1105.
34. Lai E, De Lepeleire I, Crumley TM, et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin Pharmacol Ther. 2007;81(6):849-857.
35. Cheng K, Wu TJ, Wu KK, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A. 2006;103(17):6682-6687.
36. Grundy SM, Vega GL, McGovern ME, etal; Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Int Med. 2002;162(14):1568-1576.
37. Knopp RH, Alagona P, Davidson M, et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism. 1998;47(9):1097-1104.
38. King JM, Crouse JR, Terry JG, Morgan TM, Spray BJ, Miller NE. Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipideinic men with hypoalphalipoproteinemia. Am J Med. 1994;97(4):323-331.
39. O'Keefe JH Jr, Harris WS, Nelson J, Windsor SL. Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. Am J Cardiol. 1995;76(7):480-484.
40. Plaisance ER Mestek ML, Mahurin AJ, Taylor JK, Moncada-Jimenez J, Grandjean PW Postprandial triglyceride responses to aerobic exercise and extended-release niacin. Am J Clin Nutr. 2008;88(1):30-37.
41. Offermanns S. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends Pharmacol Sci, 2006;27(7): 384-390.
42. Tunaru S, Kero J, Schaub A, et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med. 2003;9(3):352-355.
43. Zhang Y, Schmidt RJ, Foxworthy P, et al. Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A. Biochem Biophys Res Commun. 2005;334(2):729-732.
44. Ganji SH, Kamanna VS, Kashyap ML. Niacin and cholesterol: role in cardiovascular disease (review). J Nutr Biochem. 2003;14(6):298-305.
45. Ganji SH, Tavintharan S, Zhu D, Xing Y, Kamanna VS, Kashyap ML. Niacin noncompetitively inhibits DGAT2 but not DGAT2 activity in HepG2 cells. J Lipid Res. 2004;45(10):1835-1845.
46. Bodor ET, Offermanns S. Nicotinic acid: an old drug with a promising future. Br J Pharmacol. 2008; 153(suppl 1):S68-S75.
47. Carballo-Jane E, Gerckens LS, Luell S, et al. Comparison of rat and dog models of vasodilatation and lipolysis for the calculation of a therapeutic index for GPR109A agonists. J Pharmacol Toxicol Methods. 2007;56(3):308-316.
48. Plaisance EP, Lukasova M, Offermanns S, Zhang Y, Cao G, Judd RL. Niacin stimulates adiponectin secretion through the GPR109A receptor. Am J Physiol Endocrinal Metab. 2009;296(3):E549-E558.
49. Wang W Basinger A, Neese RA, Christiansen M, Hellerstein MK. Effects of nicotinic acid on fatty acid kinetics, fuel selection, and pathways of glucose production in women. Am J Physiol Endocrinol Metab. 2000;279(1):E50-E59.
50. Vega GL, Cater NB, MeguroS, Grundy SM. Influence of extended-release nicotinic acid on nonesterified tatty acid flux in the metabolic syndrome with atherogenic dyslipidemia. Am J Cardiol. 2005;95(11):1309-1313.
51. Plaisance EP, Grandjean PW, Brunson BL, Judd RL. Increased total and high-molecular weight adiponectin after extended-release niacin. Metabolism. 2008;57(3):404-409.
52. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab. 2002;13(2):84-89.
53. Smith BK, Sun GY, Donahue OM, Thomas TR. Exercise plus n-3 fatty acids: additive effect on postprandial lipemia. Metabolism. 2004;53(10):1365- 1371.
54. Bucher HC, Hengstler R Schindler C, Meier G. N-3 polyunsaturated tatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med. 2002.112(4):298-304.
55. Baillie RA, Takada R, Nakamura M, Clarke SD. Coordinate induction of peroxisomal acyl-CoA oxidase and UCP-3 by dietary fish oil: a mechanism for decreased body Fat deposition. Prostaglandins Leukot Essent Fatty Acids. 1999;60(5-6):351-356.
56. Jump DB. The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem. 2002;277(11):8755-8758.
57. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A. 1997;94(9): 4312-4317.
58. Dunstan DW Mori TA, Puddey IB, et al. The independent and combined effects of aerobic exercise and dietary fish intake on serum lipids and glycemic control in NIDDM. A randomized controlled study. Diabetes Care. 1997;20(6):913-921.
59. Hill AM, Buckley JD, Murphy KJ, Howe PR. Combining fish-oil supplements with regular aerobic exercise improves body composition and cardiovascular disease risk factors. Am J Clin Nutr. 2007;85(5): 1267-1274.
60. Warner JG Jr, Ullrich IH, Albrink MJ, Yeater RA. Combined effects of aerobic exercise and omega-3 tatty acids in hyperlipidemic persons. Med Sci Sports Exerc. 1989;21(5):498-505.
61. Brilla LR, Landerholm TE. Effect of fish oil supplementation and exercise on serum lipids and aerobic fitness. J Sports Med Phys Fitness. 1990;30(2):173-180.
62. Thomas TR, Fischer BA, Kist WB, Horner KE, Cox RH. Effects of exercise and n-3 fatty acids on postprandial lipemia. J Appl Physiol. 2000;88(6):2199-2204.
63. Thomas TR, Liu Y, Linden MA, Rector RS. Interaction of exercise training and n-3 tatty acid supplementation on postprandial lipemia. Appl Physiol Nutr Metab. 2007;32(3):473-480.
64. Farese RV Jr, Yost TJ, Eckel RH. Tissue-specific regulation of lipoprotein lipase activity by insulin/glucose in normal-weight humans. Metabolism. 1991;40:214-216.
65. Herzberg GR, Rogerson M. The effect of dietary fish oil on muscle and adipose tissue lipoprotein lipase. Lipids. 1989;24(4):351-353.
66. Cannon C, Steinberg BA, Murphy SA, Mega JL, Brunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48(3):438-445.
67. DuLay D, LaHaye SA, Lahey KA, Day AG. Efficacy of alternate day versus daily dosing of rosuvastatin. Can J Cardiol. 2009;25(2):e28-e31.
68. Branch! A, Fiorenza AM, Rovellini A, et al. Lowering effects of four different statins on serum triglyceride level. Eur J Clin Pharmacol 1999;55(7):499-502.
69. Eagles CJ, Kendall MJ, Maxwell S. A comparison of the effects of flu-vastatin and bezafibrate on exercise metabolism: a placebo-controlled study in healthy nonnolipidaeniic subjects. Brit J Clin Pharmacol. 1996;41(5):381-387.
70. Morris R, Robinson G, Tilyard M, Gurr E. Pravastatin and risk factor modification in patients with moderate primary hypercholesterolaeinia. N Z Med J. 1996; 109(1028):319-322.
71. Brown MS, Goldstein JL. A proteolytic pathway that controls the choles-terol content of membranes, cells, and blood. Proc Natl Acad Sei USA. 1999;96(20):11041-11048.
72. Thompson GR, Naouinova RP, Watts GF. Role of cholesterol in regulating apolipoprotein B secretion by the liver. J Lipid Res. 1996;37(3):439-447.
73. Duane WC, Hunninghake DB, Freeman ML, Pooler PA, Schlasner LA, Gebhard RL. Simvastatin, a competitive inhibitor of HMG-CoA reduc-tase, lowers cholesterol saturation index of gallbladder bile. Hepatology. 1988;8(5):1147-1150.
74. Sehayek E, Ono JG, Shefer S, et al. Biliary cholesterol excretion: a novel mechanism that regulates dietary cholesterol absorption. Proc Natl Acad Sei U SA. 1998;95(17):10194-10199.
75. Anderssen SA, Hjelstuen AK, Hjermann I, Bjerkan K, Holme I. Fluvastatin and lifestyle modification for reduction of carotid intima-media thick-ness and left ventricular mass progression in drug-treated hypertensives. Atherosclerosis. 2005; 178(2) :387-397.
76. Walsh JH, Yong G, Cheethain C, et al. Effects of exercise training on conduit and resistance vessel function in treated and untreated hype re hole sterolaeinic subjects. Eur Heart J. 2003;24( 18): 1681-1689.
77. United States Department of Health and Human Services. 2008 Physical Activity Guidelines for Americans. 2008. http://www.health.gov/paguide- lines/guidelines/detault.aspx. Accessed January 28, 2009.